yingweiwo

Sonepiprazole hydrochloride

Alias: PNU-101387G hydrochloride; U101387G hydrochloride; Sonepiprazole hydrochloride; 170857-36-0; Sonepiprazole (hydrochloride); orb1739218; PNU 101387; U-101387G hydrochloride
Sonepiprazole (PNU-101387G) hydrochloride is a selective D4 dopamine antagonist with Ki values of 3.6, 10.1, 5147, and 7430 nM for rD4 dopamine, hD4.2 dopamine, rD2 dopamine, and histamine H1 receptors, respectively.
Sonepiprazole hydrochloride
Sonepiprazole hydrochloride Chemical Structure CAS No.: 170857-36-0
Product category: Dopamine Receptor
This product is for research use only, not for human use. We do not sell to patients.
Size Price
500mg
1g
Other Sizes

Other Forms of Sonepiprazole hydrochloride:

  • Sonepiprazole mesylate
  • Sonepiprazole (PNU-101387G; U-101387G)
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Product Description
Sonepiprazole (PNU-101387G) hydrochloride is a selective D4 dopamine antagonist with Ki values of 3.6, 10.1, 5147 and 7430 nM for rD4 dopamine, hD4.2 dopamine, rD2 dopamine and histamine H1 receptors, respectively.
Biological Activity I Assay Protocols (From Reference)
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C21H28CLN3O3S
Molecular Weight
437.98
Exact Mass
437.154
CAS #
170857-36-0
Related CAS #
170858-34-1; 170857-36-0; 170858-33-0
PubChem CID
23288824
Appearance
Typically exists as solids at room temperature
LogP
0
Hydrogen Bond Donor Count
2
Hydrogen Bond Acceptor Count
6
Rotatable Bond Count
5
Heavy Atom Count
29
Complexity
593
Defined Atom Stereocenter Count
0
SMILES
Cl[H].S(C1C([H])=C([H])C(=C([H])C=1[H])N1C([H])([H])C([H])([H])N(C([H])([H])C1([H])[H])C([H])([H])C([H])([H])[C@@]1([H])C2=C([H])C([H])=C([H])C([H])=C2C([H])([H])C([H])([H])O1)(N([H])[H])(=O)=O
InChi Key
LMERFPJRWBLXAM-BOXHHOBZSA-N
InChi Code
InChI=1S/C21H27N3O3S.ClH/c22-28(25,26)19-7-5-18(6-8-19)24-14-12-23(13-15-24)11-9-21-20-4-2-1-3-17(20)10-16-27-21;/h1-8,21H,9-16H2,(H2,22,25,26);1H/t21-;/m0./s1
Chemical Name
4-[4-[2-[(1S)-3,4-dihydro-1H-isochromen-1-yl]ethyl]piperazin-1-yl]benzenesulfonamide;hydrochloride
Synonyms
PNU-101387G hydrochloride; U101387G hydrochloride; Sonepiprazole hydrochloride; 170857-36-0; Sonepiprazole (hydrochloride); orb1739218; PNU 101387; U-101387G hydrochloride
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
Solubility (In Vivo)
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

Injection Formulations
(e.g. IP/IV/IM/SC)
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution 50 μL Tween 80 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO 400 μLPEG300 50 μL Tween 80 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).
View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO 100 μLPEG300 200 μL castor oil 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (i.e. 100 μL Ethanol 100 μL Cremophor 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH 400 μLPEG300 50 μL Tween 80 450 μL Saline)


Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).
View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders


Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.2832 mL 11.4160 mL 22.8321 mL
5 mM 0.4566 mL 2.2832 mL 4.5664 mL
10 mM 0.2283 mL 1.1416 mL 2.2832 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
# Sonepiprazole (PNU-101387G, selective D4 dopamine receptor antagonist, Pfizer, discontinued post negative Phase 2 schizophrenia trial)
Single oral ascending dose first-in-human Phase 1 safety, tolerability, CNS PK and D4 receptor occupancy PD study of Sonepiprazole in healthy adult volunteers
CTID: Not Applicable
Phase: Phase 1
Status: Completed
Date: 1996
Phase 1 crossover PK substudy evaluating food effect, age, mild hepatic/renal impairment on systemic oral Sonepiprazole exposure
CTID: Not Applicable
Phase: Phase 1 Substudy
Status: Completed
Date: 1997
Phase 1 neuroimaging PD substudy measuring cerebral D4 receptor occupancy via SPECT radiotracer in healthy subjects
CTID: Not Applicable
Phase: Phase 1 Imaging PD Substudy
Status: Completed
Date: 1997
Multinational randomised double-blind triple-arm placebo + active-controlled pivotal Phase 2 trial of oral Sonepiprazole for acute schizophrenia (467 patients; arms: multiple Sonepiprazole doses, Olanzapine comparator, placebo; primary endpoint PANSS total score change at week 6)
CTID: Not Applicable
Phase: Phase 2
Status: Completed, negative efficacy; full program terminated
Date: 1998
Retrospective Phase 2 subgroup secondary analysis substudy of Sonepiprazole stratified by baseline positive/negative/cognitive schizophrenia symptom severity
CTID: Not Applicable
Phase: Phase 2 Retrospective Substudy
Status: Completed
Date: 1999
Discontinued exploratory Phase 2 proof-of-concept trial planned for mild cognitive impairment and stress-associated cognitive dysfunction (halted after schizophrenia trial failure)
CTID: Not Applicable
Phase: Planned Phase 2
Status: Discontinued
Date: 2000
Preclinical in vitro radioligand receptor binding selectivity assay of Sonepiprazole; >200-fold D4 vs D2/D3 dopamine receptor selectivity, minimal off-target monoamine receptor affinity
CTID: Not Applicable
Phase: Preclinical Biochemical
Status: Completed
Date: 1994
Ex vivo rodent prefrontal cortex slice electrophysiology study of Sonepiprazole-mediated glutamatergic synaptic plasticity modulation
CTID: Not Applicable
Phase: Preclinical Neurophysiology
Status: Completed
Date: 1995
In vivo rodent behavioural pharmacology preclinical study: reversal of apomorphine-induced prepulse inhibition deficit and amphetamine behavioural sensitization
CTID: Not Applicable
Phase: Preclinical Behavioural Efficacy
Status: Completed
Date: 1995
28-day & 90-day repeat oral dose toxicology preclinical trial of Sonepiprazole in rats and cynomolgus monkeys assessing CNS, hepatic, renal and haematologic safety endpoints
CTID: Not Applicable
Phase: Preclinical Toxicology
Status: Completed
Date: 1996
Radiolabeled [¹⁴C]-Sonepiprazole whole-body ADME biodistribution & blood-brain barrier penetration preclinical study across rodent and primate species
CTID: Not Applicable
Phase: Preclinical ADME
Status: Completed
Date: 1996
Modern in vitro off-target profiling follow-up study identifying dual carbonic anhydrase inhibitory activity of Sonepiprazole sulfonamide scaffold
CTID: Not Applicable
Phase: Preclinical Mechanism Follow-Up
Status: Completed
Date: 2026
Contact Us